(Tiper Stock Exchange) – Erfo Pharmaceutical Laboratory (Erfo), Innovative SME and benefit company operating throughout the nutraceutical sector chain, ha signed today a binding agreement for the acquisition of 65% of BodySano France SAS (“BodySano” or the “Target”).
Alessandro Cutè, President and Chief Executive Officer of Erfo, commented: “This operation marks a fundamental turning point in the company’s history. Thanks to the industrial synergies that see Erfo’s commercial and production know-how merge with BodySano’s knowledge of the territory, we aim to grow throughout the French and Belgian territory with the Dietnatural model and vertically integrate the BodySano production chain, significantly improving its margins with targeted interventions already identified by our management”.
Thanks to the acquisition of BodySano, Erfo enters the French and Belgian market and factors in new elements in the Diètnatural format, including new methodologies and approaches to nutritional coaching, associated with the marketing of food supplements and aesthetic treatments with innovative tools.
BodySano markets food supplements through its own brand franchise centers in France and through a direct center in Belgium.
Target management estimates revenues as at 31 December 2022 of around 1 million euro, EBITDA margin and NFP substantially in line with what was achieved as at 30 September 2022. The company specifies that “net of some extraordinary costs for strategic consultancy which will not in the new post-acquisition perimeter, it is estimated that the 2022 adjusted EBITDA margin would be between 15% and 20%”.